Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Hypertriglyceridemia HELP
Based on 2,657 articles published since 2008
||||

These are the 2657 published articles about Hypertriglyceridemia that originated from Worldwide during 2008-2019.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline The new cholesterol treatment guidelines from the American College of Cardiology/American Heart Association, 2013: what clinicians need to know. 2014

Lim, Tanna H / Orija, Israel B / Pearlman, Brian L / Anonymous4450811 / Anonymous4460811. ·Department of Internal Medicine, Atlanta Medical Center, Atlanta, GA. tannalim@yahoo.com. ·Postgrad Med · Pubmed #25387212.

ABSTRACT: The new American College of Cardiology/American Heart Association blood cholesterol guidelines of 2013 are the first major revision of cholesterol therapy guidance in over a decade. Commonly used low-density lipoprotein cholesterol (LDL-C) target goals have been abrogated in favor of intensity of statin therapy, more in line with data from randomized clinical trials. Four groups of adult patients have been identified from these studies who will most benefit from statins: patients with atherosclerotic cardiovascular disease (ASCVD); patients with primary elevations of LDL-C ≥ 190 mg/dL; diabetic patients between age 40 and 75 years without ASCVD whose LDL-C is between 70 and 189 mg/dL; and patients between age 40 and 75 years without ASCVD or diabetes with LDL-C between 70 and 189 mg/dL and an estimated 10-year ASCVD risk of 7.5% or higher. This last primary prevention group has engendered the most controversy because the newly recommended risk calculator may overestimate risk or the 7.5% threshold may be too low, thereby subjecting too many patients to statins unnecessarily. This review summarizes the latest guidelines and pertinent evidence, and provides case examples to help clinicians familiarize themselves with the new recommendations.

2 Guideline [V Brazilian Guidelines on Dyslipidemias and Prevention of Atherosclerosis]. 2013

Xavier, H T / Izar, M C / Faria Neto, J R / Assad, M H / Rocha, V Z / Sposito, A C / Fonseca, F A / dos Santos, J E / Santos, R D / Bertolami, M C / Faludi, A A / Martinez, T L R / Diament, J / Guimarães, A / Forti, N A / Moriguchi, E / Chagas, A C P / Coelho, O R / Ramires, J A F. · ·Arq Bras Cardiol · Pubmed #24217493.

ABSTRACT: -- No abstract --

3 Guideline Endocrine society releases guidelines on diagnosis and management of hypertriglyceridemia. 2013

Anonymous4570766. · ·Am Fam Physician · Pubmed #23939649.

ABSTRACT: -- No abstract --

4 Guideline Role of omega-3 ethyl ester concentrate in reducing sudden cardiac death following myocardial infarction and in management of hypertriglyceridemia: an Indian consensus statement. 2012

Dalal, J J / Kasliwal, R R / Dutta, A L / Sawhney, J P S / Iyengar, S S / Dani, S / Desai, N / Sathyamurthy, I / Rao, D / Menon, A / Dasbiswas, A / Wander, G S / Chadha, M / Hiremath, M S / Roy, D G / Gupta, V / Shivakadaksham, N. ·Kokilaben Dhirubhai Ambani Hospital, Mumbai, India. jjdalal@hotmail.com ·Indian Heart J · Pubmed #23102390.

ABSTRACT: INTRODUCTION: Sudden cardiac death (SCD) is the most lethal manifestation of heart disease. In an Indian study the SCDs contribute about 10% of the total mortality and SCD post ST elevation myocardial infarction (MI) constitutes for about half of total deaths. OBJECTIVE: Given the limitations of existing therapy there is a need for an effective, easy to use, broadly applicable and affordable intervention to prevent SCD post MI. Leading cardiologists from all over India came together to discuss the potential role of n-3 acid ethyl esters (90%) of eicosapentaenoic acid (EPA) 460 mg & docosahexaenoic acid (DHA) 380 mg in the management of post MI patients and those with hypertriglyceridemia. RECOMMENDATIONS: Highly purified & concentrated omega-3 ethyl esters (90%) of EPA (460 mg) & DHA (380 mg) has clinically proven benefits in improving post MI outcomes (significant 15% risk reduction for all-cause mortality, 20% risk reduction for CVD and 45% risk reduction in SCD in GISSI-Prevenzione trial) and in reducing hypertriglyceridemia, and hence, represent an interesting option adding to the treatment armamentarium in the secondary prevention after MI based on its anti-arrhythmogenic effects and also in reducing hypertriglyceridemia.

5 Guideline Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. 2012

Berglund, Lars / Brunzell, John D / Goldberg, Anne C / Goldberg, Ira J / Sacks, Frank / Murad, Mohammad Hassan / Stalenhoef, Anton F H / Anonymous3880736. ·University of California, Davis, Sacramento, California 95817, USA. ·J Clin Endocrinol Metab · Pubmed #22962670.

ABSTRACT: OBJECTIVE: The aim was to develop clinical practice guidelines on hypertriglyceridemia. PARTICIPANTS: The Task Force included a chair selected by The Endocrine Society Clinical Guidelines Subcommittee (CGS), five additional experts in the field, and a methodologist. The authors received no corporate funding or remuneration. CONSENSUS PROCESS: Consensus was guided by systematic reviews of evidence, e-mail discussion, conference calls, and one in-person meeting. The guidelines were reviewed and approved sequentially by The Endocrine Society's CGS and Clinical Affairs Core Committee, members responding to a web posting, and The Endocrine Society Council. At each stage, the Task Force incorporated changes in response to written comments. CONCLUSIONS: The Task Force recommends that the diagnosis of hypertriglyceridemia be based on fasting levels, that mild and moderate hypertriglyceridemia (triglycerides of 150-999 mg/dl) be diagnosed to aid in the evaluation of cardiovascular risk, and that severe and very severe hypertriglyceridemia (triglycerides of > 1000 mg/dl) be considered a risk for pancreatitis. The Task Force also recommends that patients with hypertriglyceridemia be evaluated for secondary causes of hyperlipidemia and that subjects with primary hypertriglyceridemia be evaluated for family history of dyslipidemia and cardiovascular disease. The Task Force recommends that the treatment goal in patients with moderate hypertriglyceridemia be a non-high-density lipoprotein cholesterol level in agreement with National Cholesterol Education Program Adult Treatment Panel guidelines. The initial treatment should be lifestyle therapy; a combination of diet modification and drug therapy may also be considered. In patients with severe or very severe hypertriglyceridemia, a fibrate should be used as a first-line agent.

6 Guideline Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. 2011

Miller, Michael / Stone, Neil J / Ballantyne, Christie / Bittner, Vera / Criqui, Michael H / Ginsberg, Henry N / Goldberg, Anne Carol / Howard, William James / Jacobson, Marc S / Kris-Etherton, Penny M / Lennie, Terry A / Levi, Moshe / Mazzone, Theodore / Pennathur, Subramanian / Anonymous3170692 / Anonymous3180692 / Anonymous3190692 / Anonymous3200692. ·University of Maryland, MD, USA. ·Circulation · Pubmed #21502576.

ABSTRACT: -- No abstract --

7 Guideline ESPEN Guidelines on Parenteral Nutrition: pancreas. 2009

Gianotti, L / Meier, R / Lobo, D N / Bassi, C / Dejong, C H C / Ockenga, J / Irtun, O / MacFie, J / Anonymous5110629. ·Department of Surgery, Milano-Bicocca University, San Gerardo Hospital, Monza, Italy. ·Clin Nutr · Pubmed #19464771.

ABSTRACT: Assessment of the severity of acute pancreatitis (AP), together with the patient's nutritional status is crucial in the decision making process that determines the need for artificial nutrition. Both should be done on admission and at frequent intervals thereafter. The indication for nutritional support in AP is actual or anticipated inadequate oral intake for 5-7 days. This period may be shorter in those with pre-existing malnutrition. Substrate metabolism in severe AP is similar to that in severe sepsis or trauma. Parenteral amino acids, glucose and lipid infusion do not affect pancreatic secretion and function. If lipids are administered, serum triglycerides must be monitored regularly. The use of intravenous lipids as part of parenteral nutrition (PN) is safe and feasible when hypertriglyceridemia is avoided. PN is indicated only in those patients who are unable to tolerate targeted requirements by the enteral route. As rates of EN tolerance increase then volumes of PN should be decreased. When PN is administered, particular attention should be given to avoid overfeeding. When PN is indicated, a parenteral glutamine supplementation should be considered. In chronic pancreatitis PN may, on rare occasions, be indicated in patients with gastric outlet obstruction secondary to duodenal stenosis or those with complex fistulation, and in occasional malnourished patients prior to surgery.

8 Editorial FISHing for the Miracle of Eicosapentaenoic Acid. 2019

Kastelein, John J P / Stroes, Erik S G. ·From the Academic Medical Center, University of Amsterdam, Amsterdam. ·N Engl J Med · Pubmed #30444682.

ABSTRACT: -- No abstract --

9 Editorial Trimming the Fat: Acetyl-CoA Carboxylase Inhibition for the Management of NAFLD. 2018

Imai, Norihiro / Cohen, David E. ·Division of Gastroenterology and Hepatology, Joan & Sanford I. Weill Department of Medicine, Weill Cornell Medical College, New York, NY. ·Hepatology · Pubmed #30076622.

ABSTRACT: -- No abstract --

10 Editorial The metabolic syndrome and the prostate. 2018

Gilling, Peter J. ·Urology, Bay of Plenty District Health Board Clinical School, Tauranga, New Zealand. ·BJU Int · Pubmed #29687952.

ABSTRACT: -- No abstract --

11 Editorial Editorial commentary: Dietary management of familial chylomicronemia syndrome. 2016

Williams, Lauren / Wilson, Don P. ·Cardiovascular Health and Risk Reduction Program, Cook Children's Medical Center, Fort Worth, TX, USA. Electronic address: lauren.williams2@cookchildrens.org. · Cardiovascular Health and Risk Reduction Program, Cook Children's Medical Center, Fort Worth, TX, USA. ·J Clin Lipidol · Pubmed #27206931.

ABSTRACT: -- No abstract --

12 Editorial Significant hypertriglyceridaemia and HDL cholesterol assays. 2016

Twomey, Patrick. ·Clinical Chemistry, St Vincent's University Hospital, Dublin, Ireland p.twomey@svuh.ie. ·Ann Clin Biochem · Pubmed #26960352.

ABSTRACT: -- No abstract --

13 Editorial Hemolyzed blood as a clue to the diagnosis of abdominal pain. 2016

Tariq, Raseen / Khanna, Sahil. ·Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. · Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. khanna.sahil@mayo.edu. ·Intern Emerg Med · Pubmed #26345537.

ABSTRACT: -- No abstract --

14 Editorial [Hypertriglyceridemia and LMF 1: Another piece of the puzzle]. 2015

Valdivielso, Pedro. ·Unidad de Lípidos, Hospital Virgen de la Victoria,, Málaga, España; Departamento de Medicina y Dermatología, Instituto de Biomedicina de Málaga (IBIMA), Universidad de Málaga, Málaga, España. Electronic address: valdivielso@uma.es. ·Clin Investig Arterioscler · Pubmed #26398545.

ABSTRACT: -- No abstract --

15 Editorial Nonfasting Lipid Profiles: The Way of the Future. 2015

Langsted, Anne / Nordestgaard, Børge G. ·Department of Clinical Biochemistry and the Copenhagen General Population Study, Herlev and Gentofte Hospital, Copenhagen University Hospital, Denmark; Faculty of Health and Medical Sciences, University of Copenhagen, Denmark. ·Clin Chem · Pubmed #26206883.

ABSTRACT: -- No abstract --

16 Editorial Challenges in the treatment of hypertriglyceridemia: glass half empty or half full? 2015

Sahebkar, Amirhossein / Watts, Gerald F. ·Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. ·Expert Rev Clin Pharmacol · Pubmed #26044648.

ABSTRACT: Fasting and postprandial hypertriglyceridemia appear to be causally related to atherosclerotic cardiovascular disease, and plasma triglyceride (TG) concentrations above 10 mmol/l increase susceptibility to acute pancreatitis. Exclusion of secondary causes of hypertriglyceridemia and implementation of lifestyle measures are the initial treatment in all types of hypertriglyceridemia. Current evidence regarding the benefit of adding non-statin agents, i.e. fibrates and n-3 polyunsaturated fatty acids, to statins in patients with hypertriglyceridemia (plasma 2.3 < TG ≤ 5.7 mmol/l) is insufficient. Therefore, the clinical use of non-statin agents in this context requires a careful trade-off between anticipated benefits and potential adverse events within the context of a clinical consultation. It is reasonable to consider adding fenofibrate to a maximally tolerated dose of a statin with or without ezetimibe in higher risk patients with metabolic syndrome or established atherosclerotic cardiovascular disease with persistent, residual elevation in TG > 2 mmol/l. Patients with very high fasting plasma TG levels (>10 mmol/l) need immediate expert review to offset pancreatitis and, along with strict dietary control and triglyceride-lowering pharmacotherapy, may need lipoprotein apheresis or plasma exchange.

17 Editorial Are Elevated Serum Triglycerides Really a Risk Factor for Coronary Artery Disease? 2015

Reiner, Željko. ·Department of Internal Medicine, University Hospital Centre Zagreb, School of Medicine, University of Zagreb, Croatia. ·Cardiology · Pubmed #25968652.

ABSTRACT: -- No abstract --

18 Editorial Whole Exome Sequencing in Monogenic Dyslipidemias. 2015

Tada, Hayato / Kawashiri, Masa-Aki / Yamagishi, Masakazu / Hayashi, Kenshi. ·Division of Cardiovascular Medicine, Kanazawa University Graduate School of Medicine. ·J Atheroscler Thromb · Pubmed #25911986.

ABSTRACT: -- No abstract --

19 Editorial Mendel, molecular biology, and apolipoprotein C-III: a heady combination. 2015

Patel, Shailendra B. ·Clement J. Zablocki VAMC and Division of Endocrinology, Diabetes, and Clinical Nutrition, Medical College of Wisconsin , Milwaukee, Wisconsin. ·Metab Syndr Relat Disord · Pubmed #25569471.

ABSTRACT: -- No abstract --

20 Editorial Dual role of circulating angiopoietin-like 4 (ANGPTL4) in promoting hypertriglyceridemia and lowering proteinuria in nephrotic syndrome. 2014

Vaziri, Nosratola D / Moradi, Hamid. ·University of California Irvine, Irvine, CA. Electronic address: ndvaziri@uci.edu. · University of California Irvine, Irvine, CA. ·Am J Kidney Dis · Pubmed #24838183.

ABSTRACT: -- No abstract --

21 Editorial Treatment of nephrotic syndrome: retrospection. 2014

Yee, Jerry. · ·Adv Chronic Kidney Dis · Pubmed #24602460.

ABSTRACT: -- No abstract --

22 Editorial Reaching hypertriglyceridemia goals. 2014

Katsiki, Niki / Athyros, Vasilios G / Karagiannis, Asterios / Mikhailidis, Dimitri P. ·Second Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippokration Hospital , Thessalonika , Greece. ·Curr Med Res Opin · Pubmed #24164231.

ABSTRACT: -- No abstract --

23 Editorial The editor's roundtable: hypertriglyceridemia. 2013

Friedewald, Vincent E / Ballantyne, Christie M / Bays, Harold E / Jones, Peter H. ·Associate Editor, The American Journal of Cardiology, and Clinical Professor of Medicine, University of Texas Health Science Center, Houston, Texas. Electronic address: vef@argus1.com. ·Am J Cardiol · Pubmed #24079443.

ABSTRACT: -- No abstract --

24 Editorial Emerging approaches for the treatment of hypertriglyceridemia. 2013

Rizzo, Manfredi / Perez-Martinez, Pablo / Nikolic, Dragana / Montalto, Giuseppe / Lopez-Miranda, Jose. ·University of Palermo, Biomedical Department of Internal Medicine and Medical Specialties , Via del Vespro, 141, 90127, Palermo , Italy +39 091 6552945 ; +39 091 6552945 ; manfredi.rizzo@unipa.it. ·Expert Opin Pharmacother · Pubmed #24011268.

ABSTRACT: Hypertriglyceridemia is frequent in diabetic and obese subjects, who are at increased risk for cardiovascular diseases (CVD). Increased triglycerides (TG) are a hallmark of atherogenic dyslipidemia, representing a marker of atherogenic small dense low-density lipoproteins (sdlDL). Importantly, non-fasting/postprandial TG measurements tend to be emphasized in clinical practice for the prediction of CVD, and TG-lowering agents (primarily fibrates) have a beneficial effect on atherogenic dyslipidemia, reducing TG-rich particles and ultimately lowering the production of sdlDL. The combination of omega-3 fatty acids and statins is also recommended, and widely used in clinical practice for subjects with hypertriglyceridemia. However, a consensus on the optimal clinical use of these pharmacological agents is not fully established yet, and additional large clinical studies are needed. It seems that there is a favorable association between fish consumption and mortality from CVD, but it remains to be confirmed by future trials. Finally, there are a number of novel therapies, such as those targeting microsomal transport protein and its inhibitors, which represent new promising option for treating subjects with hypertriglyceridemia.

25 Editorial Apolipoprotein C-III: going back to the future for a lipid drug target. 2013

Huff, Murray W / Hegele, Robert A. · ·Circ Res · Pubmed #23704213.

ABSTRACT: -- No abstract --

Next